Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

Hoth Therapeutics, Inc. announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases, which are rare diseases that affect less than 200,000 people in the US. HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers.